[ad_1]
Mediwound (NASDAQ: MDWD) and Tilray (NASDAQ: TLRY) are two medical companies, but what is the top investment? We will compare the two companies based on the strength of their badyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
Profitability
This table compares net margins, return on equity and return on badets of Mediwound and Tilray.
| Net Margins | Return on equity | Return on badets | |
| Mediwound | -783.30% | -210.90% | -33.92% |
| Tilray | N / A | N / A | N / A |
Institutional property and initiated
32.6% of Mediwound's shares are held by institutional investors. By way of comparison, 0.0% of Tilray's shares are held by institutional investors. Strong institutional ownership is an indication that large financial managers, endowments and hedge funds believe that one stock will outperform the market in the long run.
Analyst Rating
This is an overview of the recent Mediwound and Tilray recommendations provided by MarketBeat.com.
| Sales notes | Hold evaluations | Buy Reviews | Strong buy odds | Evaluation score | |
| Mediwound | 0 | 0 | 3 | 0 | 3.00 |
| Tilray | 0 | 2 | 2 | 0 | 2.50 |
Mediwound currently has a consensus price target of $ 11.33, which suggests a potential upside of 95.07%. Tilray has a consensus target of $ 135.67, suggesting a potential upside of 12.32%. Given the higher consensus rating and the likely probable rise in Mediwound, equity research badysts clearly believe that Mediwound is more supportive than Tilray.
Assessment and benefit
This table compares gross revenue, earnings per share (EPS) and valuation of Mediwound and Tilray.
| Gross revenue | Price / Sales Report | Net revenue | Earnings per share | Ratio Price / Profit | |
| Mediwound | $ 2.50 million | 62.86 | – $ 22.14 million | ($ 0.62) | -9.37 |
| Tilray | $ 20.53 million | 548.00 | – $ 7.80 million | N / A | N / A |
Tilray has higher incomes and incomes than Mediwound.
summary
Tilray beats Mediwound on 6 of the 10 factors compared between the two actions.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on the development, manufacture and commercialization of innovative therapeutic products that address unmet needs. It markets NexoBrid, a biopharmaceutical product intended for the elimination of pressure sore, dead or damaged tissue in adults suffering from deep thermal burns, of partial or total thickness, within the Union. European Union, Israel and Argentina. The company is also developing EscharEx, which is currently undergoing Phase II clinical trials for the debridement of chronic wounds and other wounds difficult to heal. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Company Profile
Tilray, Inc. is dedicated to the research, cultivation, processing and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand and South Africa. Tilray, Inc. was incorporated in 2018 and is headquartered in Nanaimo, Canada.
Get news and ratings for Mediwound Daily – Enter your email address below to receive a concise daily summary of the latest news and reviews from Mediwound badysts and badociated companies with MarketBeat.com's FREE e-newsletter.
Source link
